{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:13:12Z","timestamp":1790187192153,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The National Key Research and Development Program of China","award":["2022YFC2705103"],"award-info":[{"award-number":["2022YFC2705103"]}]},{"name":"The National Key Research and Development Program of China","award":["2022YFC2705100"],"award-info":[{"award-number":["2022YFC2705100"]}]},{"DOI":"10.13039\/501100017623","name":"Zhejiang Provincial Outstanding Youth Science Foundation","doi-asserted-by":"publisher","award":["LTGD24H050002"],"award-info":[{"award-number":["LTGD24H050002"]}],"id":[{"id":"10.13039\/501100017623","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024646275"],"award-info":[{"award-number":["2024646275"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>IgA vasculitis (IgAV) is the most prevalent form of vasculitis in children. While most cases of IgAV present with mild clinical symptoms and generally have a favorable prognosis, some children with IgAV nephritis may experience persistent heavy proteinuria, which is at risk of progressing to end-stage renal disease. Despite the administration of various immunosuppressive agents, treatment outcomes for these children are often suboptimal. We report the case of an 8-year-and-four-month-old girl who initially presented with rashes on both lower limbs for a duration of four days and abdominal pain persisting for two days. Renal biopsy subsequently confirmed a diagnosis of IgAV nephritis, specifically type IIIb. Despite undergoing treatment with methylprednisolone sodium succinate, cyclophosphamide, mycophenolate mofetil, leflunomide, rituximab, dapagliflozin, and other medications for over two years, her urinary protein levels remained at least 1000\u00a0mg\/24\u00a0h. One month after initiating treatment with telitacicept, the patient\u2019s urinary protein levels decreased, and two months later, they became negative. Notably, even after discontinuing immunosuppressants and glucocorticoids, the girl achieved sustained clinical remission. This case serves as a valuable clinical reference for the use of telitacicept in the treatment of refractory IgAV nephritis.<\/jats:p>","DOI":"10.1007\/s13730-025-00983-6","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T18:55:26Z","timestamp":1740855326000},"page":"402-407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept"],"prefix":"10.1007","volume":"14","author":[{"given":"Yanyan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiqin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"issue":"5","key":"983_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00281-021-00874-9","volume":"43","author":"E Pillebout","year":"2021","unstructured":"Pillebout E, Sunderk\u00f6tter C. IgA vasculitis. Semin Immunopathol. 2021;43(5):729\u201338.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"983_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18(1):22\u201334.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"983_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-005-1903-z","volume":"20","author":"WL Chang","year":"2005","unstructured":"Chang WL, Yang YH, Wang LC, Lin YT, Chiang BL. Renal manifestations in Henoch-Sch\u00f6nlein purpura: a 10-year clinical study. Pediatr Nephrol. 2005;20(9):1269\u201372.","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"983_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1136\/adc.2009.182394","volume":"95","author":"O Jauhola","year":"2010","unstructured":"Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, H\u00f6ltt\u00e4 T, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child. 2010;95(11):877\u201382.","journal-title":"Arch Dis Child"},{"issue":"9334","key":"983_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S0140-6736(02)09835-5","volume":"360","author":"J Ronkainen","year":"2002","unstructured":"Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet. 2002;360(9334):666\u201370.","journal-title":"Lancet"},{"issue":"10","key":"983_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2014.126","volume":"10","author":"JC Davin","year":"2014","unstructured":"Davin JC, Coppo R. Henoch-Schonlein purpura nephritis in children. Nat Rev Nephrol. 2014;10(10):563\u201373.","journal-title":"Nat Rev Nephrol"},{"issue":"4S","key":"983_CR7","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes KDIGO Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes KDIGO Glomerular Diseases Work Group. KDIGO 202 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1\u2013276.","journal-title":"Kidney Int"},{"issue":"9","key":"983_CR8","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","volume":"58","author":"S Ozen","year":"2019","unstructured":"Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology. 2019;58(9):1607\u201316.","journal-title":"Rheumatology"},{"key":"983_CR9","doi-asserted-by":"publisher","first-page":"1759720X2110596","DOI":"10.1177\/1759720X211059610","volume":"13","author":"MH Abu-Zaid","year":"2021","unstructured":"Abu-Zaid MH, Salah S, Lotfy HM, El Gaafary M, Abdulhady H, Tabra SAA, et al. Consensus evidence-based recommendations for treat-to-target management of immunoglobulin A vasculitis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211059610.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"14","key":"983_CR10","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Telitacicept: first approval. Drugs. 2021;81(14):1671\u20135.","journal-title":"Drugs"},{"issue":"Suppl 2","key":"983_CR11","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","volume":"16","author":"SC Yeo","year":"2023","unstructured":"Yeo SC, Barratt J. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii9\u201318.","journal-title":"Clin Kidney J"},{"issue":"3","key":"983_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2022","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P, Xing G, et al. Randomized phase 2 trial of telitacicept in patients with iga nephropathy with persistent proteinuria. Kidney Int Rep. 2022;8(3):499\u2013506.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"983_CR13","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3390\/jcm10112310","volume":"10","author":"E Pillebout","year":"2021","unstructured":"Pillebout E. IgA vasculitis and IgA nephropathy: same disease. J Clin Med. 2021;10(11):2310.","journal-title":"J Clin Med"},{"key":"983_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.771619","volume":"12","author":"Y Song","year":"2021","unstructured":"Song Y, Huang X, Yu G, Qiao J, Cheng J, Wu J, et al. Pathogenesis of IgA vasculitis: an up-to-date review. Front Immunol. 2021;12: 771619.","journal-title":"Front Immunol"},{"issue":"4","key":"983_CR15","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306\u201313.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"983_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5301\/jn.5000218","volume":"26","author":"G Xin","year":"2013","unstructured":"Xin G, Shi W, Xu LX, Su Y, Yan LJ, Li KS. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol. 2013;26(4):683\u201390.","journal-title":"J Nephrol"},{"issue":"11","key":"983_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003099","volume":"95","author":"YL Zhai","year":"2016","unstructured":"Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H. Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine (Baltimore). 2016;95(11): e3099.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"983_CR18","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s11255-021-03094-0","volume":"54","author":"J Xia","year":"2022","unstructured":"Xia J, Wang M, Jiang W. New insights into pathogenesis of IgA nephropathy. Int Urol Nephrol. 2022;54(8):1873\u201380.","journal-title":"Int Urol Nephrol"},{"key":"983_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/470803","volume":"2011","author":"M Tanaka","year":"2011","unstructured":"Tanaka M, Seki G, Someya T, Nagata M, Fujita T. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy. Clin Dev Immunol. 2011;2011: 470803.","journal-title":"Clin Dev Immunol"},{"issue":"9","key":"983_CR20","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1681\/ASN.2012010053","volume":"23","author":"F Berthoux","year":"2012","unstructured":"Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23(9):1579\u201387.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"983_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ki.2012.197","volume":"82","author":"N Zhao","year":"2012","unstructured":"Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012;82(7):790\u20136.","journal-title":"Kidney Int"},{"key":"983_CR22","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2024.11081","author":"Y Jin","year":"2024","unstructured":"Jin Y, He X, Lin W, Peng Z, Li W, Xiang W, et al. Serum cytokine profiles in children with IgA vasculitis with nephritis. Biomol Biomed. 2024. https:\/\/doi.org\/10.17305\/bb.2024.11081.","journal-title":"Biomol Biomed"},{"key":"983_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103291","volume":"148","author":"L Zeng","year":"2024","unstructured":"Zeng L, Yang K, Wu Y, Yu G, Yan Y, Hao M, et al. Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun. 2024;148: 103291.","journal-title":"J Autoimmun"},{"issue":"10","key":"983_CR24","doi-asserted-by":"publisher","first-page":"sfae285","DOI":"10.1093\/ckj\/sfae285","volume":"17","author":"M Wang","year":"2024","unstructured":"Wang M, Ma J, Yao L, Fan Y. Efficacy and safety of telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study. Clin Kidney J. 2024;17(10):sfae285.","journal-title":"Clin Kidney J"},{"issue":"4","key":"983_CR25","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1002\/mco2.515","volume":"5","author":"L Ji","year":"2024","unstructured":"Ji L, Geng Y, Zhang X, Deng X, Song Z, Tan M, et al. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept. MedComm. 2024;5(4):e515.","journal-title":"MedComm"},{"issue":"1","key":"983_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12884-024-06632-7","volume":"24","author":"X Du","year":"2024","unstructured":"Du X, Tian G, Lu X. Successful pregnancy in a patient with IgA nephropathy treated with telitacicept: a case report. BMC Pregnancy Childbirth. 2024;24(1):432.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"4","key":"983_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y, et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2024;83(4):475\u201387.","journal-title":"Ann Rheum Dis"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-00983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-00983-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-00983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T15:01:42Z","timestamp":1748790102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-00983-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-00983-6","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study has been ethically reviewed and approved by the Ethics Committee of Children\u2019s Hospital, Zhejiang University School of Medicine, as indicated by the IRB approval number (2024-IRB-0263-P-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from guardians of the participating child.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}